You are here

MK-0616

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

Drugs.com

Mon, 08/28/23 - 08:23 pm

clinical trials

hypercholesterolemia

Merck bets big on oral PCSK9 inhibitor, putting 6-year outcome study at heart of phase 3 program

Fierce Biotech

Fri, 08/25/23 - 09:57 am

PCSK9 inhibitors

clinical trials

cardiovascular disease

Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

Endpoints

Mon, 03/6/23 - 11:15 pm

clinical trials

Can A New Cholesterol Drug Restore Merck’s Prominence In Heart Drugs?

Forbes

Tue, 02/1/22 - 10:48 am

PCSK9 inhibitors

Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol

Endpoints

Mon, 11/15/21 - 10:57 am

oral PCSK9 inhibitors

PCSK9 inhibitors